

Amendments To Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (original) A method for preparing a differentiated cell, comprising the steps of: A) obtaining a mixture by mixing a) an adipose-derived precursor cell, and b) a differentiated cell corresponding to a desired site; and B) culturing the mixture under sufficient conditions which allow the adipose-derived precursor cell to differentiate.

2. (currently amended) [[A]] The method according to claim 1, wherein the differentiated cell is a mesenchymal cell.

3. (currently amended) [[A]] The method according to claim 1, wherein the differentiated cell is selected from the group consisting of adipocytes, bone marrow cells, osteoblasts, chondrocytes, fibroblasts, myofibroblasts, nerve cells, skeletal muscle cells, cardiac muscle cells, vascular endothelial cells, vascular smooth muscle cells, hepatic cells, and renal cells.

4. (currently amended) [[A]] The method according to claim 1, wherein the adipose-derived precursor cell is a cell expressing at least one protein selected from the group consisting of CD13, CD29, CD34, CD36, CD44, CD49d, CD54, CD58, CD69, CD71, CD73, CD90, CD105, CD106, CD151, and SH3.

5. (currently amended) [[A]] The method according to claim 4, wherein the adipose-derived precursor cell is a cell expressing CD13, CD29, CD34, CD36, CD44, CD49d, CD54, CD58, CD69, CD71, CD73, CD90, CD105, CD106, CD151, and SH3.

6. (currently amended) [[A]] The method according to claim 4, wherein the adipose-derived precursor cell is the cell further expressing at least one protein selected from the group consisting of CD31, CD45, CD117, and CD146.

7. (currently amended) [[A]] The method according to claim 1, wherein the adipose-derived precursor cell is a cell not expressing CD56.

8. (currently amended) [[A]] The method according to claim 1, wherein the adipose-derived precursor

cell is a cell expressing CD49d but not CD56.

9. (currently amended) [[A]] The method according to claim 1, further comprising providing an agent for promoting differentiation into a differentiated cell.

10. (currently amended) [[A]] The method according to claim 1, wherein the mixture is cultured in a medium containing at least one ingredient selected from the group consisting of adrenocortical steroids, insulin, glucose, indomethacin, isobutyl-methylxanthine (IBMX), ascorbic acid and a derivative thereof, glycerophosphate, estrogen and a derivative thereof, progesterone and a derivative thereof, androgen and a derivative thereof, growth factors, pituitary gland extracts, pineal body extracts, retinoic acid, vitamin D, thyroid hormone, fetal bovine serum, equine serum, human serum, heparin, sodium hydrogen carbonate, HEPES, albumin, transferrin, selenates, linoleic acid, 3-isobutyl-1-methylxanthine, demethylating agent, histone deacetylating agents, activin, cytokine, hexamethylenebisacetamide (HMBA), dimethylacetamide (DMA), dibutyl cAMP (dbcAMP), dimethylsulfoxide (DMSO), iododeoxyuridine (IdU), hydroxyurea (HU), cytosine arabinoside (AraC), mitomycin C (MMC), sodiumbutyrate (NaBu), polybrene, and selenium.

11. (currently amended) [[A]] The method according to claim 1, wherein the abundance ratio of the adipose-derived precursor cell to the differentiated cell corresponding to the desired site is higher than the abundance ratio of a stem cell to the differentiated cell in healthy tissue at the desired site.

12. (currently amended) [[A]] The method according to claim 1, wherein the proportion of the adipose-derived precursor cell in the mixture is higher than the proportion of a stem cell in healthy tissue at the desired site.

13. (currently amended) [[A]] The method according to claim 1, wherein the proportion of the adipose-derived precursor cell in the mixture is about 2 to about 10 times higher than the proportion of a stem cell in healthy tissue at the desired site.

14. (withdrawn) A cell mixture, comprising: an adipose-derived precursor cell; and a differentiated cell corresponding to a desired site.

15. (withdrawn) A cell mixture according to claim 14, wherein the abundance ratio of the adipose-derived precursor cell to the differentiated cell corresponding to the desired site is higher than the abundance ratio of a stem cell to the differentiated cell in healthy tissue at the desired site.
16. (withdrawn) A cell mixture according to claim 14, wherein the abundance ratio of the adipose-derived precursor cell to the differentiated cell corresponding to the desired site is about 2 to about 10 times higher than the abundance ratio of a stem cell to the differentiated cell in healthy tissue at the desired site.
17. (withdrawn) A cell mixture according to claim 14, wherein the abundance ratio of the adipose-derived precursor cell to the differentiated cell corresponding to the desired site is about 2 to about 5 times higher than the abundance ratio of a stem cell to the differentiated cell in healthy tissue at the desired site.
18. (withdrawn) A cell mixture according to claim 14, wherein the cell mixture is exposed under sufficient conditions which allow the adipose-derived precursor cell to differentiate.
19. (withdrawn) A cell mixture according to claim 14, wherein the differentiated cell corresponding to the desired site is an adipocyte, and the proportion of the adipose-derived precursor cell in the mixture is higher than the proportion of the adipose-derived precursor cell in fat tissue.
20. (withdrawn) A cell mixture according to claim 19, wherein the proportion of the adipose-derived precursor cell in the mixture is higher than the proportion of the adipose-derived precursor cell in healthy tissue at the desired site.
21. (withdrawn) A cell mixture according to claim 19, wherein the proportion of the adipose-derived precursor cell in the mixture is about 2 to about 10 times higher than the proportion of the adipose-derived precursor cell in healthy tissue at the desired site.
22. (withdrawn) A cell mixture according to claim 19, wherein the adipose-derived precursor cell is derived from suctioned fat.

23. (withdrawn) A cell mixture according to claim 19, wherein the adipose-derived precursor cell is derived from a liquid portion of an aspirate from liposuction.
24. (withdrawn) A composition for cell implantation, comprising: a) an adipose-derived precursor cell; and b) a differentiated cell corresponding to a desired site.
25. (withdrawn) A composition according to claim 24, wherein the composition is implanted into the desired site.
26. (withdrawn) A composition according to claim 24, wherein the differentiated cell is a mesenchymal cell.
27. (withdrawn) A composition according to claim 24, wherein the differentiated cell is selected from the group consisting of adipocytes, bone marrow cells, osteoblasts, chondrocytes, fibroblasts, myofibroblasts, nerve cells, skeletal muscle cells, cardiac muscle cells, vascular endothelial cells, vascular smooth muscle cells, hepatic cells, and renal cells.
28. (withdrawn) A composition according to claim 24, wherein the differentiated cell is provided in suctioned fat.
29. (withdrawn) A composition according to claim 24, wherein the differentiated cell is provided in a liquid portion of an aspirate from liposuction.
30. (withdrawn) A composition according to claim 24, further comprising at least one ingredient selected from the group consisting of adrenocortical steroids, insulin, glucose, indomethacin, isobutyl-methylxanthine (IBMX), ascorbic acid and a derivative thereof, glycerophosphate, estrogen and a derivative thereof, progesterone and a derivative thereof, androgen and a derivative thereof, growth factors, pituitary gland extracts, pineal body extracts, retinoic acid, vitamin D, thyroid hormone, fetal bovine serum, equine serum, human serum, heparin, sodium hydrogen carbonate, HEPES, albumin, transferrin, selenates, linoleic acid, 3-isobutyl-1-methylxanthine, demethylating agent, histone deacetylating agents, activin, cytokine, hexamethylenebisacetamide (HMBA), dimethylacetamide (DMA), dibutyl cAMP (dbcAMP), dimethylsulfoxide (DMSO), iododeoxyuridine (IdU), hyroxurea

(HU), cytosine arabinoside (AraC), mitomycin C (MMC), sodium butyrate (NaBu), polybrene, and selenium.

31. (withdrawn) A composition according to claim 24, wherein the adipose-derived precursor cell is allogenic to the differentiated cell.

32. (withdrawn) A composition according to claim 24, wherein the adipose-derived precursor cell is isologous to the differentiated cell.

33. (withdrawn) A method for treatment or prevention of a disease, a disorder or an abnormal condition attributed to the deficiency of a differentiated cell, comprising the steps of: A) providing a composition comprising: a) an adipose-derived precursor cell; and b) a differentiated cell corresponding to a desired site; and B) administering the composition to a subject.

34. (withdrawn) A medicament for treatment or prevention of a disease, a disorder or an abnormal condition attributed to the deficiency of a differentiated cell, comprising: a) an adipose-derived precursor cell; b) a differentiated cell corresponding to a desired site; and c) a pharmaceutically acceptable carrier.

35. (withdrawn) Use of a mixture of: a) an adipose-derived precursor cell; and b) a differentiated cell corresponding to a desired site, for preparation of a medicament for treatment or prevention of a disease, a disorder or an abnormal condition attributed to the deficiency of a differentiated cell.

36. (withdrawn) A method for treatment or improvement of a cosmetic condition, comprising the steps of: A) providing a composition comprising: a) an adipose-derived precursor cell; and b) a differentiated cell corresponding to a desired site; and B) administering the composition to a subject.

37. (withdrawn) A method according to claim 36, wherein the differentiated cell corresponding to the desired site is an adipocyte.

38. (withdrawn) A method according to claim 36, wherein the differentiated cell corresponding to the desired site is derived from abdominal fat.

39. (withdrawn) A method according to claim 36, wherein the cosmetic condition is of chest.
40. (withdrawn) A method according to claim 36, further comprising obtaining the differentiated cell corresponding to the desired site from fat of the subject.
41. (withdrawn) A method according to claim 40, the step of obtaining fat is performed by suctioning fat.
42. (withdrawn) A method according to claim 36, further comprising obtaining the adipose-derived precursor cell from the abdomen of the subject.
43. (withdrawn) A method according to claim 36, further comprising obtaining the adipose-derived precursor cell from suctioned fat of the subject.
44. (withdrawn) A method according to claim 43, further comprising obtaining the adipose-derived precursor cell from a liquid portion of an aspirate from liposuction.
45. (withdrawn) A medicament for treatment or improvement of a cosmetic condition, comprising: a) an adipose-derived precursor cell; b) a differentiated cell corresponding to a desired site; and c) a pharmaceutically acceptable carrier.
46. (withdrawn) A medicament according to claim 45, wherein the cosmetic condition is of chest.
47. (withdrawn) A medicament according to claim 45, wherein the differentiated cell corresponding to the desired site is an adipocyte.
48. (withdrawn) A medicament according to claim 45, wherein the differentiated cell corresponding to the desired site is an abdominal adipocyte.
49. (withdrawn) A medicament according to claim 45, wherein the adipose-derived precursor cell is derived from abdominal fat.

50. (withdrawn) A medicament according to claim 45, wherein the proportion of the adipose-derived precursor cell in the medicament is higher than the proportion of a stem cell in healthy tissue at the desired site.
51. (withdrawn) A medicament according to claim 45, wherein the pharmaceutically acceptable carrier comprises a cell culture medium or a buffer.
52. (withdrawn) Use of a mixture of: a) an adipose-derived precursor cell; and b) a differentiated cell corresponding to a desired site, for preparation of a medicament for treatment or improvement of a cosmetic condition.
53. (withdrawn) Use according to claim 52, wherein the abundance ratio of the adipose-derived precursor cell to the differentiated cell corresponding to the desired site is higher than the abundance ratio of a stem cell to the differentiated cell in healthy tissue at the desired site.
54. (withdrawn) Use according to claim 52, wherein the proportion of the adipose-derived precursor cell in the mixture is about 2 to about 10 times higher than the proportion of a stem cell in healthy tissue at the desired site.